MarketPulse

misleading statements

533 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

EOS Energy Faces Class Action Lawsuit Over Production Delays and Guidance Failures

Class action lawsuit filed against $EOSE for allegedly concealing production ramp failures, battery line downtime, and quality delays from November 2025 to February 2026.
EOSEsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Lawsuit Over Manufacturing Claims and Regulatory Missteps

Rosen Law Firm urges $INO investors to join class action lawsuit alleging false statements about manufacturing deficiencies and regulatory prospects.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Navan Faces Major Class Action Over Undisclosed Expenses, Stock Down 60%

Law firm launches class action against $NAVN over alleged failure to disclose surge in sales and marketing expenses following October 2025 offering.
NAVNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Oracle Faces Class Action Over AI Infrastructure Spending Disclosure, Investor Deadline Looms

Gross Law Firm sues Oracle for alleged false AI infrastructure statements; shareholders who bought stock June-December 2025 can claim damages by April 6, 2026.
ORCLORCLpDsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Bath & Body Works Faces Securities Lawsuit Over False Growth Claims

The Gross Law Firm reminds shareholders of March 13, 2026 deadline to seek lead plaintiff status in securities fraud lawsuit against $BBWI over alleged false growth guidance.
KDMETCMETCBMETCIMETCZ+1securities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

BellRing Brands Faces Securities Class Action Over RTD Sales Growth Claims

The Gross Law Firm filed a class action lawsuit against $BRBR, alleging misrepresented organic sales growth and downplayed competitive pressures in ready-to-drink category.
BRBRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

$CORT Faces Securities Lawsuit Over Relacorilant Approval Claims

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Hit With Class Action Over Failed Clinical Trials and Misleading Statements

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Ramaco Resources Faces Class Action Over Brook Mine Misrepresentations

Law firm files class action against Ramaco Resources alleging executives misrepresented Brook Mine development progress, harming shareholders between July-October 2025.
METCMETCBMETCIMETCZsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Hit With Securities Fraud Class Action Over Relacorilant Claims

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Boston Scientific Faces Class Action Over Q4 Earnings Miss; Stock Drops 17.6%

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.
BSXALITAQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Hit With Securities Lawsuit Over Gene Therapy Misstatements

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.
RGNXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Enphase Energy Faces Class Action Over Channel Inventory, Tax Credit Claims

Enphase Energy faces class action lawsuit over alleged misstatements on inventory management and tax credit impacts. Lead plaintiff deadline: April 20, 2026.
ENPHsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

BellRing Brands Faces Securities Fraud Lawsuit Over Misleading Sales Claims

Class action lawsuit alleges BellRing made false statements about sales performance, concealing inventory hoarding as genuine demand. Stock crashed 51.6% total.
BRBRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

PomDoctor Hit With Securities Fraud Class Action Over Stock Manipulation Scheme

PomDoctor faces class action lawsuit alleging securities fraud through social media manipulation, insider stock dumping via offshore accounts, and artificial price inflation. Lead plaintiff deadline: April 6, 2026.
POMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Faces Class Action Over Alleged Misstatements on Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.
VTGNsecurities fraudclass action lawsuit
BenzingaBenzinga··Prnewswire

CLEUF Hit With Securities Fraud Suit Over Alleged Pump-and-Dump Scheme

Law firm sues China Liberal Education Holdings for failing to disclose pump-and-dump manipulation and non-bona fide transactions, harming investors.
CLEUFsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Setrusumab Trial Failures

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Vistagen Faces Class Action Lawsuit Over Failed Trial, Stock Crashes 80%

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.
VTGNclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Mereo BioPharma Faces Class Action Over Failed Drug Trials; Stock Crashes 87.7%

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.
MREOsecurities fraudclass action lawsuit